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S1 - THE POWER OF PATHOLOGY - INFLUENCE OF MUTATIONAL STATUS 
IN NSCLC ON ONCOLOGICAL TREATMENT
Lejla Alidžanović Nurkanović1, Dalma Udovičić-Gagula2
1Clinic for Oncology and Radiotherapy, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina  
2Department of Pathology, Clinical Center University of Sarajevo, Sarajevo, Bosnia and Herzegovina
The identification of numerous gene alterations in the past decade had a major impact on the treat-
ment of Non Small Cell Lung Cancer (NSCLC). These driver mutations lead to specific biochemical path-
ways, which further promote growth and survival of cancer cells. There are several important mutations 
which represent well establish targets in the treatment of NSCLC. The first discovered drug-sensitive 
mutation in NSCLC was Epidermal Growth Factor Receptor (EGFR). The inhibition of EGFR has led the 
way for targeted therapy in the treatment of NSCLC. Erlotinib, the first anti-EGFR antibody was first 
approved in 2004. At first, the approval was referred to unselected patients after failure of chemotherapy, 
but was later proven to be superior in comparison with chemotherapy as first-line treatment of metastatic 
NSCLC with sensitizing EGFR mutations. Today, there are a variety of other anti-EGFR antibodies, such 
as gefitinib, afatinib, osimertinib or dacomitinib. The analyzes of phase 3 randomized trial FLAURA, 
showed superiority of osimertinib in first-line therapy with osimertinib in metastatic NSCLC with EGFR 
mutations regardless of T790M status. Antoher dirver mutation, found in approximately 5% of patients 
with NSCLC is ALK gene rearrangemet, also known as ALK fusion. This mutation is not routinely found 
in patients with squamous cell carcinoma, and therefore it is recommended to test for ALK fusions in 
patients with metastatic non-squamous NSCLC, based on the data showing efficacy of different kinase 
inhibitors, such as alectinib, brigatinib, ceritinib and crizotinib. ROS1 gene rearrangements (also known as 
ROS1 fusions) occur in about 1% to 2% of patients with NSCLC. There are different fusion partners that 
can be detected in NSCLC: CD74, SLC34A2, CCDC6 and FIG. The benefit of crizotinib, ceritinib and entrec-
tinib for patients with ROS1 fusions was shown in different trials. Aditionally, there are others gene alter-
ations, such as BRAF V600E mutation. These patients have a significant benefit in the treatment with 
combination of BRAF and MEK inhibitors dabrafenib and trametinib. Detection of RET rearrangements is 
predictive for the treatment with TKIs selpercatinib and pralsetinib. Furthermore, NTRK, METex14, KRAS 
mutations are proven to be very efficacious molecular biomarkers in the treatment of NSCLC. Testing for 
the expression of immune biomarker PD-L1 is crucial predictive biomarker for the treatment with immune 
checkpoint inhibitors. IHC testing for PD-L1 expression should be performed before first-line treatment in 
all patients with metastatic NSCLC. There are different checkpoint inhibitors (pembrolizumab, atezoli-
zumab, nivolumab, ipilimumab, cemiplimab), which showed efficacy alone or in combination with other 
treatment regimens. Testing of lung cancer specimens for these alterations is important for identification 
of potentially efficacious targeted therapies, as well as avoidance of therapies unlikely to provide clinical 
benefit. With the invention of targeted therapies and antibodies directed against tyrosine kinases and 
other specific driver mutations, the treatment options in lung cancer changed from histology-based to 
molecular and biomarker-based treatment. These changes in the treatment of NSCLC put in spotlight the 
significance of the cooperation between oncology and pathology.
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S2 - RADIOTHERAPY OF CNS METASTASES IN HER2 POSITIVE  
AND TRIPLE NEGATIVE DISEASE
Katarina Antunac
Division of Oncology and Radiotherapy, University Hospital for Tumors,  
Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Brain metastases occur in about 30- 50% of patients with HER2 positive and 40% of patients with 
triple negative breast cancer. Occurrence of CNS metastases is a marker of aggressive disease. Median 
overall survival of patients with brain metastases is 13 – 19 months in patients with HER2 positive disease 
and 4.4 months in patients with triple negative disease. Regarding radiotherapy, breast cancer brain 
metastases are treated the same as metastases from all other tumor sites. When setting up an indication for 
local treatment, crucial is to have information about the control of extracranial disease, possibility of fur-
ther systemic therapy lines and patient’s performance status. Local therapy consists of surgical treatment, 
with or without consolidation stereotactic radiotherapy and radiotherapy as a sole modality. Preferred 
method of radiotherapy would be stereotactic radiotherapy (SRT), in patients with up to 10-15 metastases, 
limiting factor being the volume of the disease (up to 15 mL). With STR local control can be achieved in up 
to 60% of patients. Fractionated stereotactic radiotherapy (FSRT), delivered in 3 to 12 fractions provides 
1- year local control rate in up to 80% of patients. In case stereotactic radiotherapy is not available or pos-
sible, patients with good performance status and extracranial disease control could be referred to whole 
brain radiotherapy (WBRT), which palliates symptoms in about 60% of patients. Both stereotactic and 
whole brain radiotherapy are connected with cognitive impairment, which is more often after WBRT. 
WBRT induced cognitive toxicity can be lowered by using hippocampal sparing radiation techniques. 
WBRT after SRT or neurosurgical procedure improves local control but has no effect on overall survival 
and can also lead to cognitive impairment. Therefore, WBRT is not indicated after these procedures. Upon 
neurosurgical operation, SRT of resection cavity should be performed, as it lowers the risk if intracranial 
relapse of the disease. There are several ongoing trials exploring different radiotherapy techniques (SRT or 
WBRT), and their timing and combination with various systemic agents in breast cancer patients with 
brain metastases, such as lapatinib, trastuzumab emtansine, pembrolizumab. In patients with low perfor-
mance status, loss of extracranial disease control and short life expectancy, it would be reasonable to omit 
whole brain radiotherapy since it has no effect on survival or quality of life and the same palliative effect 
can be achieved with corticosteroids use only.
Keywords:  CNS metastases, HER2 positive breast cancer, triple negative breast cancer, radiotherapy, 
SRT, WBRT, FSRT
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S3 - THE ROLE OF IMMUNOTHERAPY IN METASTATIC COLORECTAL 
CANCER TREATMENT - IS THERE A ROOM FOR IMPROVEMENT?
Borislav Belev
Department of Medical Onology, Clinical Hospital Center Zagreb, Zagreb, Croatia
Immunotherapy has evolved recently as very promising and possibly effective treatment of several 
tumor types. Immunotherapy has dramatically changed treatment landscape of some entities, but benefit 
in colorectal cancer was so far very modest due to fact that only up to 5% of patients with mCRC have high 
microsatelite instability and mismatch-repair deficient genes. These features are considered as biologic 
markers for tumors which we expect to respond to immunotherapy. According to data obtained from 
early clinical studies (phase II) and last year presented phase III study, KEYNOTE-177, led to FDA-
approval of pembrolizumab in first line treatment of metastatic colorectal cancer in June 2020. KEY-
NOTE-177 was a randomized, open-label study enrolling 307 treatment-naive patients with microsatelite 
instability-high/mismatch repair-deficient (MSI-H/dMMR) mCRC. Randomization was 1:1 to treatment 
with pembrolizumab or investigator’s choice of doublet chemotherapy (n=154) meaning standard of care. 
Dual primary endpoint were PFS and OS, and crossover was permitted at disease progression. This is very 
important trial, since it was the first randomized- trial evaluating first-line pembrolizumab in patients 
with metastatic colorectal cancer. This was especially critical for Europe, because pembrolizumab was not 
approved. It is worth to mention that about 25% of patients had BRAF V600E-mutant tumor sin the trial. 
Median PFS2 was not reached in the pembrolizumab group and was 23.5 months in the chemotherapy 
group (HR:0.63)(ASCO GI 2021). The 12-month rate was PFS2 76% for pembrolizumab and 67% for che-
motherapy. The same tendency was at 24-month PFS2. The rate of adverse events (AEs) and treatment-
related AEs was similar in both treatment arms. Grade ≥ 3 treatment-related AEs were much more com-
mon in the chemotherapy group, affecting 66% of the patients compared with 22% of the patients receiv-
ing pembrolizumab. Grade ≥ 3 diarrhea, fatigue, and neutropenia also were significantly higher in the 
chemotherapy group. These results were expected, as pembrolizumab is generally well-tolerated. Gener-
ally, quality of life did not decrease in pembrolizumab group (QoL scores), and pain and appetite loss also 
improved with pembrolizum vs chemotherapy. So, there was a clear benefit in both PFS and QoL for the 
use of pembrolizumab over chemotherapy. The rate of adverse events (AEs) and treatment-related AEs 
was similar in both treatment arms. Grade ≥ 3 treatment-related AEs were much more common in the 
chemotherapy group, affecting 66% of the patients compared with 22% of the patients receiving pembro-
lizumab. Grade ≥ 3 diarrhea, fatigue, and neutropenia also were significantly higher in the chemotherapy 
group. These results were expected, as pembrolizumab is generally well-tolerated. Although this results 
put immunotherapy as very attractive treatment modality, there are many questions still to be answered 
in the future. We still don’t know the relationship between KRAS-mutant phenotype and immunotherapy, 
as well as the meaning of other biomarkers. After all, some patients do not respond to immunotherapy, so 
in the near future we should define which patients would be optimal for immunotherapy in first line set-
ting and which would benefit from chemotherapy, nevertheless.
Keywords: immunotherapy, pembrolizumab, colorectal cancer, chemotherapy
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S4 - THE BEST APPROACH TO SYSTEMIC THERAPY IN FIRST LINE 
TREATMENT OF ADVANCED/METASTATIC HCC
Emina Bičakčić Filipović, Elma Kapisazović
Department of Oncology, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Bacground: Hepatocellular carcinoma is fourth leading cause of death among cancer patients. This 
cancer is four to eight times more common in the male population and is usually associated with chronic 
liver damage (hepatitis B (HBV), hepatitis C (HCV) and alcoholic cirrhosis). Cirrhosis, regardless of the 
cause, is present in 70-80% of HCC cases. Chronic infection with HBV and cirrhosis increases the possibil-
ity of HCC up to 100 times. 5-30% of patients with HCV infection develop chronic liver disease, > 30% 
progress to cirrhosis, and in that population, 1-2% of them develop HCC annually. Co-infection with HBV 
further increases the risk of developing the disease. Other risk factors are: alcohol abuse, autoimmune 
diseases (autoimmune hepatitis and primary biliary cirrhosis), metabolic diseases (diabetes mellitus, 
hemochromatosis, non-alcoholic steatohepatitis...) and environmental toxins (alpha-toxins, alcohol, 
tobacco). According to currently available epidemiological data, HCC still kills about 1,000,000 people a 
year, and the 5-year OS is less than 5%.
Current treatment of HCC: Historically, in the last few decades, systemic HCC therapy has relied on 
classical chemotherapy, which unfortunately has not been shown to be effective in the treatment of 
advanced or metastatic hepatocellular carcinoma. We see the first big leap in treatment in 2007 with the 
introduction of Sorafenib into clinical practice. Sorafenib, a TKI inhibitor, demonstrated in the SHARP 
study has been shown to have better OS and PFS for 3 months compared to the placebo group. Until 2017, 
Sorafenib was the only treatment option for HCC - numerous clinical studies with EGFR and VGFR, TKI 
inhibitors gave negative results (BRIK FL, LIGHT and SEARCH studies).Since 2017, the revolution in the 
treatment of this disease has continued, with the fact that in a short period of time we suddenly have more 
than 10 drugs that have FDA and EMA approval for the treatment of HCC in the first and second line. The 
first drug to show non-inferiority to Sorafenib in the REFLECT study was Lenvatinib, thus finding its place 
as another option in first-line HCC treatment. At the same time, several targeted drugs show their efficacy 
in the second line of HCC treatment - Regorafenib (RESORCE study), Cabozantinib (CELESTIAL Study) 
and Remocirumab. The concept of monoimmunotherapy, after promising results from phase 2 studies - 
Pembrolizumab and Nivolumab, has unfortunately not been confirmed in phase 3 studies, and the con-
cept of monoimmunotherapy is not recommended. Given the studies presented at ASCO GI (IMBRAVE150), 
the future of HCC treatment is most likely to be found in combinations of immunotherapy + target ther-
apy, as well as combinations of CTLA4 inhibitors and immunotherapy. IMBRAVE150 is a study that estab-
lished the combination of atezolizumab + bevacizumab as first-line therapy. The study alone included 150 
patients, randomized 2: 1, and the primary goal of the study was OS and PFS. The median PFS for the 
combination was 6.8 months, compared with 4.3 months in the Sorafenib group. The side effects shown in 
the atezolizumab and bevacizumab groups corresponded to the safety profiles of drugs known from 
before, and 15% of patients discontinued therapy due to side effects. In contrast, 10% of patients discontin-
ued Sorafenib therapy due to side effects. Combination therapy also resulted in a longer time to deteriora-
tion in quality of life than in patients on Sorafenib. A couple of phase two studies examining the efficacy 
of combinations of VEGFR inhibitors + Pembrolizumab, and a combination of CTLA4 inhibitors and 
immunotherapy showed promising results. The results of a phase III study of LEAP-002 - efficacy and 
safety of the combination of Lenvatinib and Pembrolizumab, in first-line therapy of advanced / metastatic 
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HCC, are currently expected. The primary objectives of the study are OS and PFS. Interesting results are 
also expected in the HIMALAYA phase 3 study, where the efficacy and safety of durvalumab + tremelim-
umab and durvalumab monotherapy are evaluated compared to sorafenib in the treatment of naive 
patients with unserctable HCC. The study was randomized into four groups, but it will be interesting to 
follow the results between the two combination groups Durvalumab + Tremelimubab, given the choice of 
drug dose. The COSMIC-312 study compares the efficacy of Cabozatinib + atezolizumab versus Sorafenib 
in first-line therapy. The CheckMATE-040 study investigated the efficacy and safety of Nivolumab, alone 
or in combination with immunotherapy, in patients with concomitant comorbidities.
Conclusion: After a long time, in the treatment of HCC in addition to chemotherapy, we have made 
progress in the form of targeted therapy and immunotherapy, as well as combinations of the same that are 
currently being investigated. In the end, the question remains how to further sequence HCC therapy? This 
is a question to which there is no clear answer right now, given that we have not recently had an option for 
a second line of therapy and now we already have over 10 approved drugs. Proper sequencing of therapy 
lines would greatly facilitate the treatment of patients with HCC, taking into account that patients with 
HCC are usually in a severe general condition, burdened with primary disease and concomitant comor-
bidities. Numerous clinical studies that are underway will most likely better clarify these dilemmas and 
thus enable better sequencing of the therapy itself.
Keywords:  hepatocellular carcinoma - HCC, advanced, metastatic, non-resectable, sorafenib, atezoli-
zumab, bevacizumab
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S5 - PARP INHIBITORS IN THE TREATMENT OF TRIPLE NEGATIVE  
BREAST CANCER
Simona Borštnar
Division of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
Triple negative breast cancer (TNBC) accounts for approximately 10-15% of all breast cancers and it 
is associated with a poor prognosis. TNBC are characterized by the absence of estrogen receptor (ER), 
progesterone receptor (PR), and HER2 expression, therefore chemotherapy has long time been the only 
treatment option. This has changed in the last few years. Molecular targets and target therapy were identi-
fied, namely immunotherapy with the immune checkpoint inhibitor atezolizumab in PD-L1 positive 
tumors and, the oral inhibitor of poly (adenosine diphosphate-ribose) polymerase (PARP) directed against 
mutated BRCA genes. Approximately 5 % of all breast cancer patients are BRCA mutation carriers, and 
among them, more than half have the clinical TNBC subtype, showing a high association between germ-
line (g) BRCA mutations and TNBCs. BRCA1 mutation carriers mainly develop TNBCs, whereas BRCA2 
carriers are more likely to develop ER and/or PR positive tumors. For patients with advanced breast cancer 
(ABC) who carry gBRCA mutation PARP inhibitors has shown activity in several clinical trials. OlympiAD 
and EMBRACA were the pivotal phase III trials leading to the single-agent approvals of olaparib and tala-
zoparib in gBRCA-mutated, HER2- negative ABC, previously treated with anthracycines and taxanes. The 
OlympiAD randomly assigned 302 patients to receive olaparib (300 mg bid) or standard therapy of the 
physician’s choice. Median progression-free (PFS) was significantly longer in the olaparib group than in 
the standard therapy group (7.0 months vs. 4.2. months). Overall survival (OS) did not differ between the 
two treatment groups. The subset analysis suggested that PFS improvement with olaparib appeared 
greater in the TNBC subgroup. The EMBRACA trial randomly assigned 431 patients to talazoparib (1 mg 
PO qd) or standard single-agent chemotherapy of the physician’s choice. Median PFS was significantly 
longer in the talazoparib group than in the standard therapy group (8.6 months vs. 5.6 months). Median 
OS did not differ between the two groups. The phase III BROCADE3 trial evaluated carboplatin and pacli-
taxel, with or without the PARP inhibitor veliparib. Results showed not only improvement in PFS with the 
addition of veliparib (median: 14.5 months). Recently published Cochrane systematic review confirmed 
that PARP inhibitors offer a PFS advantage and there might be a small advantage in OS for patients with 
HER2-negative, gBRCA mutated ABC. Given PARP inhibitors did not have significantly increased toxicity 
and two studies that did look at quality of life outcomes showed an improvement. Based on these results 
ABC 5 guidelines included single-agent PARP inhibitor (olaparib or talazoparib) for patients with a gBRCA 
mutation as preferred treatment option for those with triple-negative ABC and one of treatment options in 
HR-positive, HER2-negative ABC. PARP inhibitors are currently being investigated in early BC, in novel 
combinations, and in patients without germline BRCA mutations, including those with somatic BRCA 
mutations and other DNA homologous recombination mutations. Ongoing phase 2/3 studies include 
PARP inhibitors combined with immune checkpoint inhibitors for the treatment of triple-negative BC.
Keywords: triple negative breast cancer, germline BRCA mutation, PARP inhibitors
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S6 - ALK /ROS1 AND BEYOND: NOVEL MOLECULARLY DRIVEN TARGETED 
THERAPIES IN WITH NON-SMALL CELL LUNG CANCER (NSCLC)
T imur Cerić, Anes Pašić, Emina Bičakčić Filipović, Elma Kapisazović, Mujo Kadrić,  
Emir Sokolović, Emina Borovac-Gurda, Semir Bešlija
Department of Oncology, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegiovina
With the advent of genomic medicine, in NSCLC personalized oncology has helped improve treat-
ment outcomes and quality of life compared to traditional chemotherapy. Advances in the knowledge of 
pathways, technologies for detecting actionable genetic lesions, and newly developed drugs to block the 
activities of the pathways in recent years have allowed the physicians to tailor the treatment options. In 
lung adenocarcinoma, a number of targetable major pathways have been identified, such as ALK, ROS 1, 
MET, RAS–MAPK, and NTRK pathways. The discovery of the EML4-ALK fusion gene in a limited subset 
of patients affected by NSCLC and the subsequent clinical development of crizotinib in 2011 has been an 
impressive milestone in lung cancer research. Rearrangements in anaplastic lymphoma kinase (ALK) 
account for 3–7% of all non-small cell lung cancers (NSCLC). Modern tyrosine kinase inhibitors (TKIs), 
such as ceritinib, alectinib, brigatinib, and lorlatinib, have been approved for the management of anaplas-
tic lymphoma kinase (ALK)-positive NSCLCs. Treatment with targeted tyrosine kinase inhibitors (TKIs) 
has shown impressive clinical responses. Treatment sequencing today is crucial in this patient population 
due to fact that these patients are living much longer with good quality of life. ROS1-rearranged NSCLC 
is classified as a distinct molecular subset of NSCLC with a therapeutic target. ROS1 rearrangement is 
most often identified in never-smokers with adenocarcinoma and EGFR and ALK receptor tyrosine kinase 
gene (ALK) wild type. ROS1 rearrangements occur in approximately 1-2% of patients with NSCLC. ROS1-
positive lung cancer tends to be more aggressive form of disease. Treatment with tyrosine kinase inhibi-
tors (TKIs), which target the ROS1 kinase domain, is considered the standard of care. TKIs have been 
shown to have a robust and durable response. BRAF mutations, considered as alternative oncogenic driv-
ers in NSCLC, lead to constitutive activation of cell signaling pathways downstream of MAP kinase, are 
generally mutually exclusive compared to EGFR mutations and ALK and ROS1 rearrangements and, in 
contrast to these, are more frequent in smokers. 30% of NSCLC patients. BRAF V600E positive show a 
benefit if treated with a BRAF inhibitor such as vemurafenib or dabrafenib. Data also reveal that combined 
therapy with BRAF and MEK inhibitors, specifically dabrafenib and trametinib, doubling response rate 
(66.7% in previously treated patients, 64% in untreated patients) and improved disease-free survival. Gene 
rearrangements involving NTRK1/2/3 can generate fusion oncoproteins containing the kinase domains of 
TRKA/B/C, respectively. These fusions are rare in non-small cell lung cancer (NSCLC), with frequency 
previously estimated to be less 1%. Inhibition of TRK signaling has led to dramatic responses across tumor 
types with NTRK fusions. RET fusions are oncogenic drivers in 1 to 2% of non–small-cell lung cancers 
(NSCLCs). In patients with RET fusion–positive NSCLC, the efficacy and safety of selective RET inhibition 
are promising. Selpercatinib and pralsetinib have durable efficacy, including intracranial activity, with 
mainly low-grade toxic effects in patients with RET fusion–positive NSCLC. Abnormalities in the MET 
gene have been shown to be one of key drivers in the development and growth of non-small cell lung 
cancer (NSCLC). These MET abnormalities frequently occur as exon-14 skipping mutations, in which the 
MET transcript lacks exon 14. These MET exon-14-skipping mutations (METex14) are found in approxi-
mately 3%-4 % of NSCLC patients. Capmatinib is a drug for the treatment of patients with metastatic 
NSCLC who are also positive for METex14. In a key clinical trial, capmatinib showed a promising overall 
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response rate among patients: 68%, when used as the initial treatment, and 41% when used in second- and 
third-line settings. In addition, capmatinib is relatively well tolerated by patients. Because NSCLC has 
been known to metastasize to the central nervous system, it is also important to note that capmatinib can 
penetrate into the central nervous system. Taken together, these results suggest that capmatinib and some 
other agents could be a good treatment option to consider for NSCLC patients who are positive for 
METex14 mutations. Nevertheless, while target therapy in NSCLC has provided disease control, the 
tumors inevitably develop drug resistance. Understanding resistance mechanisms and developing combi-
national therapies are essential for improving the treatment outcomes.
Keywords:  non small cell lung cancer – NSCLC, ALK, ROS 1, MET, RAS-MAPK, NTRAK, target 
therapy.
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S7 - OPTIMAL SEQUENCE IN HER-2 POSITIVE METASTATIC  
BREAST CANCER
Natalija Dedić Plavetić
Department of Oncology, Division of Medical Oncology, University Hospital Center Zagreb  
and School of Medicine, University of Zagreb, Zagreb, Croatia
Breast cancer is the most commonly diagnosed cancer in female population worldwide. Advances in 
understanding tumor biology, particularly signalling pathways, have led to the development and approval 
of novel therapeutic agents, especially in HER2-positive and hormone receptor positive subtypes. For the 
decades ago there were no improvement in overall survival of patients with metastatic disease till improve-
ment in the prognosis of HER2-positive metastatic breast cancer (MBC). It has radically changed in the 
recent years mainly due to broad application of targeted therapies designed to block HER2 signalling 
pathway like monoclonal antibodies and small molecules tyrosine kinase inhibitors. HER2 signalling 
pathway is an ideal target due to persistent dependency of tumor cells on this oncogene and low expres-
sion in healthy tissues. Precise delivery of cytotoxic drugs via HER2 receptor has been recently developed. 
The first improvement was shown in a phase 3 trial by adding trastuzumab to first line taxane chemo-
therapy compared to chemotherapy alone, with almost 5 months improvement in the median overall 
survival (OS). Further improvement was reached in CLEOPATRA Phase 3 trial with addition of pertu-
zumab to trastuzumab and chemotherapy in first-line treatment of metastatic disease, with almost 16 
months in median OS improvement. Pertuzumab, humanized monoclonal antibody, targets different epi-
tope of the HER2 receptor extracellular domene thus preventing hetero dimerization of HER2 with other 
HER receptors. Dual anti HER2 antibody blockade also stimulates antibody-dependent, cell- mediated 
cytotoxicity (ADCC). In the later lines of treatment there were also some improvements, particularly by 
using antibody-drug conjugates and small molecules tyrosine kinase inhibitors. T-DM1 represents the first 
antibody–drug conjugate (ADC) approved for the treatment of MBC. ADCs are drugs consisting of a 
monoclonal antibody covalently bound to a cytotoxic drug with synthetic linker. ADCs combine the 
advantages of specific targeting through the monoclonal antibody directed against HER2 receptor and 
high cytotoxicity by the precise delivery of chemotherapeutic drug. The phase 3 registration trials, EMILIA 
and THERESA, comparing T-DM1 with capecitabine plus lapatinib and with treatment according to phy-
sician’s choice, respectively, established T-DM1 as today’s standard of care for second-line treatment of 
HER2-positive MBC and early progressor during adjuvant therapy also. Neratinib is an orally available 
irreversible pan-HER TKI, targeting HER1, HER2 and HER4. The NALA phase 3 trial compared neratinib 
plus capecitabine with lapatinib plus capecitabine in patients with HER2-positive MBC, who have received 
at least two prior anti-HER2-based regimens. Progression or death was reduced by 24% in the neratinib- 
arm compared to the lapatinib-arm with a prolongation of PFS by 2.2 months. Based on these results, the 
FDA approved neratinib in combination with capecitabine for patients with advanced HER2-positive 
breast cancer who have received at least 2 prior anti-HER2-based regimens in the metastatic setting. 
Recently, the US Food and Drug Administration (FDA) approved new drugs for the treatment of HER2-
positive MBC: the antibody–drug conjugate (ADC) trastuzumab deruxtecan (proven in the phase 2 study 
DESTINY- Breast 01) and tucatinib tested in the HER2CLIMB trial. Tucatinib is a third generation, orally 
available, highly selective inhibitor of the HER2 tyrosine kinase. In the HER2CLIMB phase II trial all 
patients had received prior treatment with trastuzumab, pertuzumab and T-DM1. Patients with brain 
metastases were included also. After failure of these two drugs, the new TKI tucatinib in combination with 
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capecitabine has prolonged PFS and OS and has achieved objective response in 40% of patients, with sig-
nificant intracranial responses and a survival advantage in patients with brain metastases. In addition, 
new ADC trastuzumab deruxtecan has shown impressive response rates and long-lasting remissions in 
heavily pre-treated patients with a median of six previous treatment lines. Such rapid developments give 
us hope in further improvements of overall survival in metastatic breast cancer patients with HER2 posi-
tive subtype, but also complicate optimal therapy sequencing. Encouraged with these recent advances 
breast cancer specialists are looking forward to new upcoming options in the treatment of metastatic 
HER2 positive breast cancer, like CDK 4/6 inhibitor and immunotherapeutic combination options.
Keywords:  metastatic breast cancer, HER2 positive, monoclonal antibodies, trastuzumab, pertuzu-
mab trastuzumab deruxtecan, neratinib, tucatinib, lapatinib
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S8 - AN UNMET NEED IN BRAF MUTANT METASTATIC MELANOMA: 
TREATMENT SEQUENCING AND LEPTOMENINGEAL DISEASE
Lidija Kandolf Sekulovic
Faculty of Medicine, Military Medical Academy, Belgrade, Serbia
In BRAF-mutant metastatic melanoma, there is a choice of first-line treatment with BRAFi+MEKi 
targeted therapy, immunotherapy (mono, or combination), and recently, in US with triple combination of 
vemurafenib+cobimetinib+atezolizumab. Since there are still no reliable predictive and prognostic bio-
markers, the choice of treatment relies on physicians’ judgment based on disease dynamics, tumor burden, 
and patients’ preference. In most of the patients with low-tumor burden the treatment is usually started 
with immunotherapy, while in disease with high tumor and symptoms, BRAFi+MEKi or combination 
anti-PD1+anti-CTLA-4 can be initiated. More mature data from clinical studies that are underway are 
eagerly awaited to answer the question of best sequence in metastatic melanoma. One of the most difficult 
clinical scenarios is leptomeningeal disease that frequently develops as a site of failure of different sys-
temic treatments. Through case report of the patient with leptomeningeal disease developing on progres-
sion to second-line treatment with BRAFi+MEKi, data from the existing clinical studies on treatment 
sequencing and treatment options for leptomeningeal disease are analyzed. Based on the recent data, 
leptomeningeal disease is still holding a dismal prognosis, with overall survival of 2.9 months. Radio-
therapy does not affect overall survival, while short-term responses to BRAFi+MEKi were described and 
rare, more durable responses to immunotherapy. Clinical studies are underway with intrathecal immuno-
therapy. Despite the great developments in the treatment of metastatic melanoma, questions about the 
treatment sequencing are still a matter of debate. Also, more data on leptomeningeal disease and search 
for the better treatment options for this group of patients are needed.
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S9 - URINARY BLADDER CARCINOMA
Suzana Matković
Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Bladder carcinoma (BC) is the most common neoplasm of the urinary system while urothelial carci-
noma (UC) is the most common histologic type of BC (approximately 90%). Management of non-muscle 
invasive UC has its basis on the risk stratification done following transurethral resection of the bladder tumor 
and relies on tumor stage, number, size, pathological grade, associated CIS, lymphovascular invasion, or 
presence of aberrant histology. All muscle-invasive tumors are categorized as high-grade urothelial carcino-
mas. Management of muscle-invasive BC has its basis in the stage and whether the patient is a surgical can-
didate and whether the patient willing to accept the consequences of radical cystectomy which is the primary 
treatment for T2 and T3 tumors, with consideration for neoadjuvant chemotherapy. Clinical evidence has 
demonstrated a overall survival benefit of neoadjuvant chemotherapy with methotrexate, vinblastine, doxo-
rubicin, and cisplatin (MVAC) or gemcitabin and cisplatin compared with cystectomy alone. Neoadjuvant 
chemotherapy for muscle invasive UC is a validated therapeutic standard that is also in the NCCN, ESMO, 
EUA recommendations with the highest level of scientific evidence-IA. Current clinical data conflict on the 
role of adjuvant therapy in invasive bladder cancer, and additional trials are required, however, results from 
trials show delays of recurrence, so chemotherapy with MVAC or gemcitabine and cisplatin may be used. 
According to NCCN recommendations, adjuvant chemotherapy can be use in T3-4 or N + (only in patients 
who did not receive neoadjuvant chemotherapy) with level of evidence 2B. Patients diagnosed with meta-
static urothelial carcinoma (mUC) have a poor 5-year relative survival rate. Metastatic disease is generally 
incurable, with a relative 5-year survival rate of ~5%. Cisplatin-containing combination chemotherapy is 
standard if first line (1L) chemotherapy in advanced or metastatic patients fit enough to tolerate cisplatin. A 
number of cisplatin-containing regimens are acceptable although gemcitabine and cisplatin is the most 
widely accepted than dose-dense methotrexate, vinblastine, doxorubicin and cisplatin (ddMVAC). How-
ever, in real clinical practice about 50% patients with metastatic UC are not “fit” for cispatin therapy. Ineligi-
bility for the use of cisplatin refers to: creatinine clearance <60mL/min, grade ≥2 audiometric hearing loss, 
NYHA Class III heart failure, WHO or ECOG PS ≥2 and grade ≥2 peripheral neuropathy. Carboplatin-based 
chemotherapy is recommended in patients “unfit” for cisplatin chemotherapy and carboplatin and gem-
citabine is the preferred regimen. Pembrolizumab or atezolizumab are second choices for patients in 1L who 
are programmed death-ligand 1 (PD-L1)-positive and not eligible for cisplatin-based chemotherapy. “Check-
point” inhibitor avelumab has found its place in maintenance therapy in patients who do not have disease 
progression after 1L of systemic therapy. There are no definitive recommendations for second-line therapy 
(2L). Options for palliative therapy depends on the therapy that was used for 1L. In patients treated with 
platinum-based chemotherapy, ESMO recommendations in 2L list the following as a standard options: 
atezolizumab, pembrolizumab, nivolumab and erdafitinib (FGFR alterations) and as alternativne options 
chemotherapy or enfortumab vedotin. If immunotherapy is administered as 1L, platinum-based chemo-
therapy should be considered in 2L as well as enfortumab vedotin and erdafitinib (if specific FGFR altera-
tions present) in patients who progress after platinum based chemotherapy and immunotherapy. Until a few 
years ago, there was no significant improvement for 1L and 2L systemic therapy for mUC patients and for 30 
years chemotherapy was therapy of choice. The therapeutic landscape has been altered and enhanced by the 
introduction of immunotherapy and new drugs like erdafitinib, a fibroblast growth factor receptor (FGFR) 
inhibitor and antibody-drug Enfortumab vedotin.
Keywords: bladder carcinoma, urothelial carcinoma, systemic therapy, immunotherapy
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S10 - NEXT GENERATION SEQUENCING
Tanja Mesti
Institute of Oncology Ljubljana, Ljubljana, Slovenia
Next generation sequencing (NGS) of tumor and inherited (germline) genomes is an DNA sequenc-
ing technology. With NGS an entire human genome can be sequenced within a single day in contrast with 
the previous Sanger sequencing technology, used to decipher the human genome, required over a decade 
to deliver the final draft. NGS has revolutionized and refined cancer treatment during the past two decades 
and is now vital for evaluating therapeutic opportunities in many solid and hematologic malignancies 
There are a number of different NGS platforms using different sequencing technologies, but all NGS plat-
forms perform sequencing of millions of small fragments of DNA in parallel. Bioinformatics analyses are 
used to piece together these fragments by mapping the individual reads to the human reference genome. 
Each of the three billion bases in the human genome is sequenced multiple times, providing high depth to 
deliver accurate data and an insight into unexpected DNA variation. NGS can be used to sequence entire 
genomes or constrained to specific areas of interest, including all 22 000 coding genes (a whole exome) or 
small numbers of individual genes. Currently, NGS panels including sets of genes are the most wide-
spread method of rapidly identifying sequence variation in patients with cancer. NGS panels provide 
information for a variety of purposes, including diagnostics (eg, determination of sarcoma subtype), 
hereditary risk assessment (eg, Lynch syndrome), prognosis (eg, KRAS mutations in lung and colorectal 
adenocarcinoma), and treatment selection (eg, biomarkers for immunotherapy responsiveness, such as 
tumor mutational burden and microsatellite instability, therapeutic selection for clinically actionable alter-
ations, such as BRAF V600E in melanoma, and biomarkers of resistance, such as loss of B2M for immuno-
therapy). The main disadvantage of NGS in the clinical setting is putting in place the required infrastruc-
ture, such as computer capacity and storage, and also the personnel expertise required to comprehensively 
analyse and interpret the subsequent data. The ESMO Translational Research and Precision Medicine 
Working Group in 2020 developed the recommendations on the basis of the ESMO Scale for Clinical 
Actionability of molecular Targets (ESCAT) ranking for genomic alterations occurring in the eight cancers 
responsible for the most deaths worldwide and NGS should be routinely used in patients with advanced 
lung adenocarcinoma, metastatic prostate and ovarian cancer and metastatic cholangiocarcinoma. Based 
on the data presented by Cobain et al. and others, it is evident that such precision medicine strategies are 
especially fruitful in cancer types without clear standard-of-care options, such as carcinoma of unknown 
primary and other rare tumors. In conclussion, as the cost-effectiveness of using multigene sequencing in 
daily practice is currently weak, the NGS should be used for subgroup of patients with advanced cancer 
and no standard therapeutic options.
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S11 - DO ALL PATIENTS WITH RECURRENT OVARIAN CANCER NEED 
SYSTEMIC THERAPY AND WHICH IS THE OPTIMAL TREATMENT 
ALGORITHM
Ivana Minić, Zorica Tomašević
Department of Medical Oncology, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia
Ovarian cancer (OC) is the sixth most frequently diagnosed female cancer and the fifth cause of cancer 
death. The average life time risk for OC is 1 / 78 females, median age at diagnosis is 63 years while OC is 
extremely rare before age 35. Mortality is high, and almost 2/3 of patient will die of recurrent OC. The most 
common histological type is the most malignant one, high grade serous carcinoma, representing ~75-80% 
of all OC. Due to unspecific symptoms, approximately 80% of patients are diagnosed in advanced stage, 
and 75- 80% will experience relapse after primary treatment median 3 years after primary diagnosis. Initial 
treatment is optimal cytoreductive surgery followed by platinum based chemotherapy and that has not 
been changed in the last almost 30 years. Relapse is almost always considered incurable, but with proper 
treatment, significant life prolongation can be achieved. The chances for the relapse of the disease are esti-
mated taking into account several factors: the stage of the disease at the moment of establishing the diag-
nosis, the success of the initial surgical treatment and accomplished cytoreduction, the level and the speed 
of growth of cancer antigen 125 and the response to the primarily administered therapy. However, even 
besides the aforementioned facts, there are not any predictive recurrence markers. Even though the treat-
ment of OC is mainly standardized and implies surgery (with the goal of complete cytoreduction) and 
administration of chemotherapy based on platinum derivatives, the recurrent disease is heterogenous and 
implies a broad spectrum of presentation in terms of the location and expansion of the very relapse as well 
as the length of the time interval from the primary treatment to the occurrence of relapse. All three therapy 
models are considered in treating recurrent OC: surgery, chemotherapy and/or targeted therapy, and radio-
therapy. In reference to the time of occurrence, recurrent OC is classified into two large groups: the group 
where the relapse occurred 6 months or more after the primary treatment and the other group where the 
relapse occurred earlier than the stated period, so-called early relapse. This classification significantly 
affects the choice of the therapy treatment. There is a special group of patients where secondary surgical 
treatment is indicated. Those are primarily fit patients, with relatively long DFI, a clear, anatomically local-
ized relapse, where a good effect of further postoperative systematic therapy is expected. In individual 
cases, intraperitoneal chemotherapy may also be administered. In the systematic treatment of recurrent 
OC, there are several therapy options. The choice of treatment is mostly affected by the performance of the 
patient in the first place, then the stage of the disease, the time elapsed from the last platinum therapy to 
the relapse, biology of the tumor, previous chemotherapy treatments and the patients’ reactions to them, 
but also the toxicity of the previous therapies. Generally, dividing patients into platinum-sensitive and 
platinum-resistant groups is the solution to the treatment algorithm for these patients. Non- platinum 
protocols are indicated for the patients with early relapse, or the progression of the disease that occurred 
during administering platinum chemotherapy, or for the patients with intolerance to platinum medica-
tion. Monotherapy, primarily paclitaxel, pegylated liposomal doxorubicin (PLD), gemcitabine, or topote-
can – is recommended for these patients. The patients who did not receive bevacizumab in the first line of 
treatment, should be given this medication along with chemotherapy. For the group of patients with plat-
inum-sensitive disease, there are several options at disposal with the addition of the targeted therapy 
which implies biological agents affecting the angiogenesis and/or DNA reparation mechanisms. The 
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detected BRCA mutation represents a predictor of a better response to platinum and introduction of poly 
(adenosine diphosphate- ribose) polymerase (PARP) inhibition. PARP inhibitors and anti-angiogenetic 
medications have a proven record as the sustainment therapy after chemotherapy, and concurrently with 
chemotherapy. These medications have changed the manner and outcome of recurrent OC treatment, 
even though a very small number of predictive biomarkers of targeted therapy are available. The patients 
who fall into the platinum-sensitive group and cannot receive the medication again should be treated with 
trabectedin and PLD, the most active non-platinum therapy in this setting.These last years, the field of 
interest has moved from chemotherapy to targeted therapy which is dominated by anti-angiogenic and 
anti-PARP agents. It is assumed that platinum-free interval will not remain the main prognostic and predic-
tive criterion in the future and will be replaced by a multi-factorial approach. This trend for personalization 
of therapy has highlighted necessary neglected fields for clinical research such as multi-line (≥3) relapse, 
frail patients including elderly and symptomatic and supportive measurements.
Keywords:  ovarian cancer, recurrence, secondary surgery, BRCA, poly (adenosine diphosphate-
ribose) polymerase (PARP) inhibitors, platinum resistance.
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S12 - SYSTEMIC TREATMENT OF MELANOMA
Janja Ocvirk
Institute of Oncology Ljubljana, Ljubljana, Slovenia
The incidence of melanoma in both men and women, has been increasing over the past 40 years 
despite stable or even declining trends for most cancers. Melanoma accounts for about 75% of deaths from 
skin cancer. More than 50% of patients have a BRAF mutation, 20% NRAS and 5% c-KIT mutation. With 
the development of modern immunotherapy: ipilimumab, pembrolizumab and nivolumab, and targeted 
therapies - BRAF and MEK inhibitors, the survival of patients with melanoma has greatly improved. 
BRAF + MEK inhibitors are suitable for patients with the BRAF mutation, and Immunotherapy is effective 
regardless of the BRAF mutation. The combination of nivolumab and ipilimumab is even more effective 
than nivolumab or pembrolizumab alone, but it also has more side effects. Combination immunotherapy 
is also highly effective in BRAF mutated patients, even more than a combination of BRAF + MEK inhibi-
tors. A series of different lines of immunotherapy or target and immunotherapy leads to further prolonga-
tion of survival. Adverse reactions associated with these new treatments are generally acceptable and mild 
to moderate, but care should be taken in the choice of treatment as specific adverse events are associated 
with these treatments. unique and serious adverse events have also been reported. Therapeutic decisions 
are increasingly complex, examining patient and disease characteristics, individual and treatment goals, 
as well as different efficacy and safety profiles of drugs with different mechanisms of action and according 
to their lines of treatment. The long-term survival of patients with advanced melanoma is now a realistic 
goal, creating an additional need to re-establish the clinical benefit assessment. The future will also bring 
us different combinations and answers about the sequence in the approach to treatment, which should 
further increase the number of patients who will benefit clinically from this type of treatment
Keywords: metastatic melanoma, immunotherapy, targeted therapy
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S13 - TREATMENT OF HER2 POSITIVE GASTRIC CANCER
Anes Pašić, Elma Kapisazović
Department of Oncology, Clinical Centre University of Sarajevo, Sarajevo, Bosnia and Herzegovina
Background: Gastric cancer is the fifth most common cancer worldwide and accounts for 6.8% of all 
cancers excluding non-melanoma skin cancer. It is the third most common cause of cancer-related mortal-
ity worldwide. Patients diagnosed at an advanced stage has very poor prognosis with 5-year survival not 
exceeding 5–20%. Systemic chemotherapy based on fluoropyrimidine and a platinum agents is the 
 standard treatment for patients with unresectable advanced gastric cancer. Role of targeted therapies is so 
far limited to trastuzumab in the first line treatment of HER2-positive tumors and ramucirumab in the 
second line.
Treatment of HER2 positive gastric cancer: The HER2 protein is overexpressed in 10–20% of patients 
with AGC. Having in mind excellent results with anti HER2 therapy in breast cancer, there was a hope that 
same can be achieved for patients with HER2 positive gastric cancer. First results were promising, in 2010, 
the phase 3 ToGA trial demonstrated the benefit of adding trastuzumab to first-line chemotherapy in 
patients with HER2-positive locally advanced, recurrent, or metastatic gastric or GEJ adenocarcinoma. 
Unfortunately, several trials in 1st and 2nd line treatment with different anti HER2 agents such as Lapatinib, 
Pertuzumab and TDM-1 failed to confirm positive results of ToGA trial. Explanation for these negative 
result lies in different biology of HER2 positive breast and gastric cancer. Mechanism of Primary Resis-
tance to Anti-HER2 agents in gastric cancer is related to fact that, unlike breast cancer, HER2 overexpres-
sion and/or amplifcation by GC can be heterogeneous which could affect response to anti-HER2 therapies. 
Also in gastric cancer primary resistence can be explained with presence of oncogenic alterations such as 
PTEN deficiency and/or PI3K-activating mutations, MET amplifcation or EGFR overexpression that can 
co-exist in HER2-amplified tumors. Proposed mechanism of Secondary Resistance to Anti-HER2 Agents 
in gastric cancer includes: loss of HER2 positivity acquired HER2 mutations, activation of alternative path-
ways, protein overexpression, epithelial to mesenchymal transition, micro RNAs. Recently two trials with 
anti-HER2 agents showed activity in gastric cancer. In the randomized, phase II trial DESTINY-Gastric01, 
trastuzumab deruxtecan (T-DXd) a novel HER2 antibody–drug conjugate demonstrated a significantly 
higher ORR as a primary endpoint and a longer OS as a secondary endpoint in patients with pretreated 
HER2-positive AGC. The ORR as the primary endpoint was significantly higher in the T-DXd group com-
pared with the physician’s choice group (51% versus 14%, p < 0.001). The median duration of response was 
11.3 months with T-DXd and 3.9 months with chemotherapy. This trial demonstrated a statistically sig-
nificant improvement in OS as a key secondary endpoint with T-DXd (median OS 12.5 versus 8.4 months, 
HR 0.59, p = 0.01). Regarding adverse events approximately 10% of patients experienced interstitial lung 
disease teleted to T-DXd. Another positive results are coming from PETRARCA trial which evaluated the 
addition of trastuzumab and pertuzumab to FLOT for HER2-positive resectable gastric cancer. In this pro-
spective, multicenter, randomized, investigator initiated trial patients with HER2+ resectable esophago-
gastric cancer (≥ cT2 or cN+) were randomized 1:1 to 4 pre- and post-operative cycles of FLOT (Arm A) or 
the same regimen with trastuzumab and pertuzumab, followed by 9 cycles trastuzumab/pertuzumab (arm 
B). Primary endpoint for the phase II part was the rate of pathological complete remission (pCR). The pCR 
rate was significantly improved with tras/per (A, 12%, B, 35%, p = 0.02). Likewise, the rate of pathological 
lymph node negativity was higher with tras/per (A, 39%, B, 68%). R0-resection rate and surgical morbidity 
were comparable. DFS and OS rates [with 95% CI] at 24 months were 54% [38-71%] and 77% [63-90%] in 
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arm A and 70% [55-85%] and 84% [72-96%] in arm B, respectively. In terms of toxicity more ≥ grade 3 
adverse events were reported with trastuzumab/pertuzumab (75% vs. 85%), especially diarrhea (5% vs. 
41%) and leukopenia (13% vs 23%). In conclusion, trastuzumab-based first-line therapy is Standard of care 
in HER2 overexpressing advanced/metastatic gastroesophageal cancer. Novel HER2 targeted approaches 
have shown great promise, in particular, antibody-drug conjugates with proof-of-efficacy even in trastu-
zumab-pretreated cancers. Promising results are also coming from PETRARCA trial in neoadjuvant set-
ting with dual anti-HER2 therapy. Ongoing trials with of anti-PD-1 and anti-HER2 therapy may further 
improve treatment results for patients with HER2 positive gastric cancer.
Keywords: gastric cancer, HER2, Petrarca,T-DXd
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S14 - STATE OF THE ART IN TREATMENT OF mRC: A CASE REPORT
Radmila Rašeta, Tamara Višekruna, Živko Vranješ, Zdenka Gojković, Milka Vještica, Dejan Đokanović
Oncology Clinic, University Clinical Centre of Republic of Srpska, Banja Luka, Bosnia and Herzegovina
The treatment of metastatic Renal Cell Carcinoma (RCC) has changed dramatically over the past two 
decades. There has been significant progress in both surgical management and development of novel thera-
peutic agents. Most patients with RCC are asymptomatic or only have mild symptoms which leads to an 
increased number of metastatic RCC at the initial diagnosis. With growing data from clinical trials and large 
number of monitored patients, prognostic scoring systems (The MSKCC criteria and IMDC or Heng’s model) 
have been developed in order to define risk groups and provide optimal treatment. Novel prognostic models 
based on genomic and molecular signatures are being developed and tested in latest trials. In some patient, 
surgical management of primary tumor and oligometastatic sites may be beneficial. Some studies have 
showed that there is no difference in overall survival but the data is unclear so surgery should be considered. 
Immunologic characteristic of RCC have been recognized a long time ago, so the use of interferon-alfa and 
interleukin-2 resulted in so-called “cytokine era” in treatment of advanced RCC before 2005. Discovery of 
new molecular pathways lead to “era of targeted therapies” that greatly improved prognosis of patients with 
metastatic RCC. In the recent years, modulation of immune response has again found an important role in 
treatment of metastatic RCC. Also combination therapy has become the focus of research including combina-
tion of immunotherapy and targeted therapy. Recent studies have showed promising results especially in 
the first line of treatment of metastatic RCC. The ultimate aim is to personalize and optimize treatment for 
each patient. We will present a patient with recurrent RCC and course of his treatment during the last fifteen 
years. The patient is a 40-year-old male who initially presented with large tumor mass in his left kidney in 
2006. After nephrectomy it was determined that it is clear cell RCC, stage III. Patent was on regular follow-
up. In 2013, seven years after nephrectomy, local recurrence of RCC occurred. The patient was treated surgi-
cally and with six cycles of first line therapy with Vinblastin/ Interferon-Alpha-2a. In 2015, one year after the 
last cycle of therapy, patient presented with a retroperitoneal tumor mass that was surgically removed and 
pathohistological report determined it to be metastasis of RCC. One year after the surgery, three new tumor 
masses were detected on the site of the primary tumor. The masses were unresectable, so the patient started 
second line of therapy with Pazopanib, due to limited therapeutic options at our institution. In the following 
two years, the patient achieved complete remission while on Pazopanib. However, the patient decided to 
stop taking Pazopanib due to reduced quality of life. In 2020, two years after the patient had stopped taking 
Pazopanib, new relapse of disease occurred, with local tumor recurrence, enlarged lymph nodes in the retro-
peritoneum, liver metastases and infiltration of descendant colon that were seen on PET/CT. The patient 
underwent hemicolectomy, but still refused further systemic treatment. The patient continued with regular 
follow-up. Recently, PET/CT showed only local recurrence without dissemination of disease. Previously 
shown liver metastasis had no metabolic activity in the latest PET/CT. The patient is in good condition but is 
still reluctant to undergo any type of systemic treatment currently available. However, radiotherapy would 
be a reasonable option as tumor is present only locally. Possible treatment options will be discussed but tak-
ing into consideration the patient’s unwillingness to receive systemic treatment, options are limited. Despite 
growing knowledge about biological nature of RCC, it still remains an unpredictable and aggressive disease. 
There is a necessity for novel therapeutic agents and regimens that would be optimized for each patent based 
on clinical and pathohistological characteristics.
Keywords: metastatic renal cell, late recurrence, pazopanib
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S15 - PARP INHIBITORS IN THE TREATMENT OF THE OVARIAN CANCER
Tajana Silovski1, Nikolina Lonjak2, Sanda Šitić3
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2Department of Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center,  
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Treatment of the ovarian cancer was until recently based on initial cytoreductive surgery followed by 
chemotherapy based on carboplatin and paclitaxel. Based on the results of randomized phase III trials 
GOG-0218 and ICON7 which confirmed progression-free survival (PFS) benefit with addition of bevaci-
zumab to chemotherapy, this combination become standard especially in high-risk patients with poor 
prognosis like stage IV disease, residual disease after suboptimal debulking or presence of ascites where 
quick response to the therapy is needed. The role of the bevacizumab in the neoadjuvant setting is less 
clear and this treatment setting still presents significant unmet patients’ need. Only few years ago the 
recurrent ovarian cancer treatment has changed enormously due to introduction of PARP inhibitors which 
were found to be effective in tumors with defects in DNA damage repair. Inhibition of PARP leads to 
propagation of single strand DNA breaks and accumulation of double strand breaks which require repair 
by homologous recombination (HR) repair mechanisms. PARP inhibitors were initially developed as 
maintenance therapy in patients with complete or partial response to platinum-based chemotherapy for 
recurrent ovarian cancer. The remarkable improvement in PFS confirmed in three randomized phase III 
trials – NOVA/ENGOT-OV16, SOLO-2/ENGOT-OV21 and ARIEL3 – led to approval of niraparib, olaparib 
and rucaparib, respectively, as highly effective maintenance therapy in this setting. Platinum sensitivity 
seems to be the most reliable biomarker for sensitivity to PARP inhibitor in recurrent disease. The greatest 
benefit was seen in BRCA-mutated population. In all three studies, exploratory analysis suggested addi-
tional antitumor activity in patients with measurable disease at the beginning of the maintenance suggest-
ing PARP inhibitor treatment role as well. PARP inhibitors changed course of disease in this setting delay-
ing need to initiate further chemotherapy. For the illustration, 11% of patients in the Study 19 were treated 
by olaparib for more than 6 years. Olaparib, rucaparib and niraparib monotherapy are also approved in 
various treatment rather than maintenance setting for pretreated recurrent ovarian cancer patients. Fur-
ther on, PARP inhibitors were investigated in randomized, altogether four, phase III trials in the front-line 
setting (SOLO-1, PAOLA-1/ENGOT-OV25, PRIMA/ENGOT-OV26 and VELIA/GOG-3005) and demon-
strated remarkable improvements in PFS with PARP inhibitor therapy (olaparib, niraparib or veliparib) 
for newly diagnosed ovarian cancer. Differences in trial design, patient selection and primary analysis 
population influence interpretation of these trials making meaningful comparisons an almost impossible 
challenge. Those differences were considered in relation to the control arms (placebo versus active drug), 
patient populations (sensitivity to induction platinum and residual disease), timing of PARP inhibitor 
initiation (concomitant with chemotherapy versus maintenance only), and planned duration of PARP 
inhibitor therapy. The treatment choice in the first line should take into consideration clinical risk factors, 
comorbidities, timing of surgery (interval versus primary debulking), residual disease, need for bevaci-
zumab, BRCA status as well as access to PARP inhibitors. Overall survival data are pending and there is 
limited experience regarding long-term safety. PARP inhibitors therefore play a pivotal role in the man-
agement of newly diagnosed ovarian cancer, which will then affect subsequent treatment choices. In newly 
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diagnosed ovarian cancer sensitivity to PARP inhibitors rely more on BRCA and HR deficiency (HRD). 
Approval of olaparib in maintenance after front-line chemotherapy is restricted to BRCA mutated disease 
if given alone and in combination with bevacizumab in HR deficient disease. Niraparib is approved as 
maintenance after front-line platinum-based chemotherapy irrespective of HR status. Accuracy and reli-
ability of currently available tests leave room for improvement by developing more robust tests. Defining 
of testing for patient selection and identification of regimens to treat populations that benefit less from 
PARP inhibitors are priority. In conclusion, new data support use of PARP inhibitors earlier in the treat-
ment algorithm.
Keywords: ovarian cancer, PARP inhibitor, BRCA mutation, HR deficiency
Lib Oncol. 2021;49(Suppl 2):1–34
24
S16 - HEAD AND NECK CARCINOMA
Robert Šeparović
Division for Medical Oncology, University Hospital for Tumors, Sestre milosrdnice University Hospital Center, 
Zagreb, Croatia and Medical School, Juraj Dobrila University of Pula, Pula, Croatia
Head and neck cancers are the sixth most common malignancy in the world, affecting about 830,000 
people a year. Risk factors are well known and are associated with the use of nicotine, alcohol and human 
papillomavirus infection. This is a heterogeneous group of diseases that in 95% of cases refers to squamous 
cell carcinomas. The dominant mode of treatment in the early stage of the disease refers to local control by 
surgery or irradiation. At an advanced stage, the disease is controlled by various forms of systemic anti-
neoplastic treatment, although we should not forget the importance of maintaining nutritional health, and 
more recently the use of radiosurgical treatment in the presence of oligometastatic disease. The basis of 
systemic treatment in advanced disease is a combination of cisplatin and 5-fluorouracil, to which cetux-
imab (EXTREME protocol) has been added since 2008. This resulted in a prolonged overall survival and 
an improved response rate. A data update published in 2014 showed that the addition of cetuximab to 
chemotherapy improved survival, regardless of p16 or HPV status. An attempt to add bevacizumab to 
standard combination chemotherapy has not been justified in terms of prolonging survival, despite a 
higher response rate and prolonging the time to disease progression. After initial knowledge of gene alter-
ations (TCGA, Nature 2015), immunotherapy was started in this vulnerable group of patients, in whom 
there were no significant therapeutic shifts for years. The significance of nivolumab in second-line treat-
ment after progression to a platinum compound within 6 months was first investigated. A shift in overall 
survival from 4.6 to 8.7 months was found in the group of patients with PD-L1 expression ³1%, with an 
overall improvement in quality of life according to the EORTC-QOL-C30 questionnaire compared to treat-
ment chosen by the researchers. In a very similar study design, pembrolizumab after platinum (KEYNOTE 
040) was administered compared to standard treatment (methotrexate, docetaxel, or cetuximab). There 
was a difference in the median OS of 8.4 vs 6.9 months, although the difference was not statistically sig-
nificant. It is also worth mentioning the increase in the overall response rate from 9.2 to 26.6%. In the 
PD-L1 TPS ³ 50% patient population, the median OS was 11.6 vs 6.6 months. The reason for the impact on 
overall survival may also be found in the fact that 12.5%  of patients who received standard treatment sub-
sequently received immunotherapy. What was expected as a turning point in the treatment of advanced 
head and neck cancer was the KEYNOTE-048 study. There, in first-line treatment, pembrolizumab was 
directly compared in monotherapy, versus combination with chemotherapy, and versus the standard 
EXTREME protocol. Pembrolizumab has been shown to be more effective in OS gain, compared to 
EXTREME, independent of CPS, as well as in combination with chemotherapy. The results of a longer 
follow-up published at ESMO 2020 showed in the group pembrolizumab vs EXTREME after 48 months OS 
16.7 vs 5.9 months (CPS ³1) and 21.6 vs 8.0 (CPS ³20). In the pembrolizumab group with chemotherapy vs 
EXTREME, the difference was 21.8 vs 4.1 (CPS ³1) and 28.6 vs 6.6 (CPS ³20). According to these results, 
EXTREME remains the standard therapy in patients who do not show PD-L1 expression, pembrolizumab 
as monotherapy becomes a therapeutic option in patients whose tumors show PD-L1 (CPS ³1), while the 
use of pembrolizumab with chemotherapy is recommended when rapid therapeutic response needed. Trk 
family proteins are encoded by NTRK genes, expressed in human neuronal tissue and activated by neuro-
trophins. Ligand binding activates downstream signal transduction pathways – MAPK, ERK, PI3K/AKT 
and plays a key role in CNS and PNS development and cell survival. Gene fusions involving NTRK genes 
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have known oncogenic potential via ligand-independent, constitutive Trk activation and mediate neoplas-
tic proliferation using the same signal transduction pathways. NTRK fusions are most commonly found in 
papillary thyroid carcinoma and salivary gland tumors, and today valid therapeutic options in this 
extremely rare group of patients are larotrectinib and entrectinib with an overall response rate of 50-79%, 
which clearly indicates the need for their detection. In a small group of patients with oligometastatic dis-
ease, radiosurgical treatment is considered. In the case of wider application of immunotherapy, synergism 
with high doses of radiation could represent a new therapeutic step forward. However, regardless of 
therapeutic advances, it should be borne in mind that head and neck cancer patients are extremely vulner-
able population of patients in whom continuous nutritional health care is required, the risk of toxicity as a 
consequence of immunotherapy should be well assessed, so multidisciplinarity as the foundation of the 
approach today has gained additional importance.
Keywords: head and neck carcinoma, pembrolizumab, NTRK genes, radiosurgical treatement
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S17 - PARP INHIBITORS IN THE TREATMENT OF PROSTATE CANCER
Boštjan Šeruga
Institute of Oncology Ljubljana, Ljubljana, Slovenia
In cancer patients with error-prone DNA repair drug-induced PARP inhibition can lead to cellular 
death. Over 20% of man with metastatic castration-resistant prostate cancer (mCRPC) have loss-of-func-
tion alterations in genes that are involved in DNA repair, including homologous recombination repair. 
These alterations can be either hereditary or somatic. The phase III trial PROfound which evaluated olapa-
rib demonstrated significant improvements in radiologic progression-free survival (rPFS) and overall sur-
vival (OS) among men in cohort A with mutations in BRCA1, BRCA2, and ATM, but not in men with 
alterations in other prespecified genes with a direct or indirect role in the homologous recombination 
repair. Similarly, phase II TRITON2 trial found benefit to rucaparib, though this was not a randomized 
comparison. Up until now somatic and/or germinal BRCA 1 and 2 alterations seem to be the most predic-
tive biomarkers of efficacy of PARP inhibitors in patients with mCRPC. While these trials provided evi-
dence of substantial clinical benefit in an advanced patient population using a biomarker-driven study 
design and have changed clinical practice, there are significant limitations as these patients are not cured 
and many responses are not durable. Further, a large proportion of biomarker-positive patients failed to 
demonstrate benefit. Results of other ongoing phase III trials assessing the efficacy of a PARPi used alone 
or in combination are awaited, to better define their place with regard to standard treatments and plati-
num-based chemotherapies.
Keywords: prostate, cancer, tretament
27
Lib Oncol. 2021;49(Suppl 2):1–34
S18 -VALUE OF ANTIHER2 TREATMENT IN BREAST CANCER
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In about a fifth of breast cancer cases, it is HER 2 positive breast cancer, which means that tumor cells 
on their surface overexpress a HER2 receptor, one that makes them more aggressive, and for years HER2 
positive breast cancer has been the most aggressive subtype of the disease in terms of frequent dissemina-
tion and death in the metastatic stage of disease. The revolution happened twenty years ago, with the 
introduction of targeted antiHER2 therapy. It all started with trastuzumab, which in the metastatic stage 
of the disease prolonged survival by several months and, in the long run, saved more than 150 000 life 
years. In the early stages of the disease, the use of trastuzumab has been shown to reduce the risk of dis-
ease recurrence and death by as much as a third. However, despite the use of standard one-year treatment 
with trastuzumab, a quarter of patients experience relapse, signaling the need to do more. The most sig-
nificant success was achieved by double HER2 blockade, trastuzumab and pertuzumab, which when 
administered together have a synergistic effect. This success is primarily reflected in the 16-month longer 
overal survival of patients with metastatic disease, who were treated with double HER2 blockade in addi-
tion to chemotherapy, compared to trastuzumab alone. In the neoadjuvant setting, a number of studies 
have shown a higher rate of achieving a complete pathological response, if pertuzumab was used in addi-
tion to trastuzumab. Adjuvantly, double blockade with trastuzumab and pertuzumab proved to be justi-
fied in patients with positive lymph nodes. In addition to monoclonal antibodies, a valuable antiHER2 
drug is trastuzumab emtansin, which acts by an antibody-drug conjugate mechanism. In metastatic dis-
ease, it has achieved valuable success in prolonging survival of patients who have progressed to previous 
antiHER2 therapy. In early stage, it halved the risk of recurrence of invasive disease, in those patients who 
did not achieve a complete response to neoadjuvant therapy. In the antiHER2 arsenal we also have several 
small molecules, respectively tyrosine kinase inhibitors, among which the first is lapatinib, which has been 
shown to be a relevant option with capecitabine chemotherapy or even with trastuzumab, in metastatic 
HER2 positive breast cancer. Unfortunately, after positive results from neoadjuvant studies, large adju-
vant studies have not confirmed the efficacy of lapatinib in the treatment of early disease, and with non-
negligible drug toxicity. Another TKi, neratinib, has been shown to be effective in the extended adjuvant 
treatment of early HER2-positive breast cancer, but also in pretreated patients with metastatic stage, how-
ever the results are not sufficient to change clinical practice and drug toxicity is significant. Is that all? 
What does the panorama of antiHER2 therapy look like today? New agents are on the horizon today, with 
new properties and benefits. An example of one is the tyrosine kinase inhibitor tucatinib, which has shown 
a significant effect on survival, again, in pretreated patients with metastatic disease, and is of particular 
interest in population with brain metastases. The next new drug that has aroused interest and hope for 
new developments and advances is trastuzumab deruxtecan, an antibody-conjugate drug, with excellent 
results in the pretreated population of patients with metastatic disease, and showing effect even in those 
with low HER2 expression. Moreover, nowadays in oncology we whitness also the advent of biosimilar 
drugs, and trastuzumab biosimilars are of particular interest, taking into account the economic factor, 
namely the financial toxicity with the original drug. However, it remains to be seen what has brought to 
us the possibility of applying biosimilar drugs, in terms of long-term open issues, in a sensitive area such 
as oncology. On the other hand, the importance of financial toxicity is being balanced also through the 
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novelties and new benefits that the original drugs still bring, such as the fixed subcutaneous combination 
of trastuzumab and pertuzumab. When we look at the other side of the coin, it is gratifying that the toxic 
profile of these drugs, especially the main one among them, trastuzumab, is very appreciative. With trastu-
zumab we monitor cardiotoxicity, while with pertuzumab we can expect some diarrhea, which is some-
what more serious with tyrosine kinase inhibitors, and with the advent of new drugs it is necessary to keep 
in mind the possibility of new, unusual toxic manifestations. Targeted anti-HER 2 therapy, especially 
trastuzumab, has revolutionized and artificially completely altered the natural course of an aggressive 
disease, such as HER 2-positive breast cancer, providing these patients with a significantly better progno-
sis in the long run, in comparison to other, naturally more indolent types of breast cancer.
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It is well known that estrogene stimuli enhance proliferation, and thus also hormone-dependent 
tumors. Among breast cancers, in over two thirds of cases, these are hormone-dependent tumors. The 
purpose of antihormonal treatment is to block the effect of estrogen on the progression of these tumors, by 
blocking the function of estrogen receptors or by blocking the production of estrogen, on the periphery or 
in the ovary. Relevant world recommendations, St Gallen, ESMO, NCCN, ASCO, in the instructions on the 
use of adjuvant antihormonal therapy in the treatment of early breast cancer somewhat differ. Certainly, 
it is recommended that in low-risk patients, at the earliest stage of the disease, five-year treatment be used, 
either with tamoxifen or aromatase inhibitor, while intensification of therapy, qualitatively or quantita-
tively, is recommended in higher stages of the disease or higher risk. Evidence for this lies in a number of 
studies and meta - analyzes, which showed that the use of tamoxifen in the treatment of breast cancer 
reduced the risk of recurrence of the disease and new breast cancer by half and the risk of death by about 
a third. Aromatase inhibitors added an additional benefit of about 4% in reducing the risk of disease recur-
rence, but without the additional survival benefit. How to create adjuvant antihormonal treatment for an 
individual patient is best examined through a complex risk analysis for each individual patient, ie the 
characteristics of the disease, but also the patient’s toxicity, general health and willingness of the patient 
to continue taking the drug after five years of therapy. In premenopausal patients, it is very important, 
with increasing risk, to introduce ovarian suppression with tamoxifen, while the use of aromatase inhibi-
tors in premenopausal patients, mandatorily with ovarian suppression, contributed to a reduction in the 
risk of disease recurrence but again, not in overall survival. Given that even after five years of adjuvant 
antihormonal therapy, the long-term risk of disease recurrence cannot be ignored, even in the smallest 
tumors, numerous studies have investigated the benefit of prolonged, so called extended adjuvant anti-
hormonal treatment. Prolongation of tamoxifen treatment has been shown to indeed bring additional 
benefit. Prolonged treatment with aromatase inhibitors has been shown to be effective in reducing the risk 
of developing secondary cancers, possibly in reducing the risk of relapse, but without affecting survival. 
Due to all the above, it is very important to decide on the use of antihormonal therapy, especially its dura-
tion, in agreement with the patient, and depending on her preferences, individual risk and tolerability of 
therapy.
Keywords:  adjuvant antihormonal treatment, endocrine treatment, tamoxifen, aromatase inhibitors, 
ovarian function supression, extended adjuvant
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Hormone receptor positive breast cancer subtype accounts for approximately 70 % of advanced breast 
cancer patients. New targeted treatment options are emerging after more than a decade without any sig-
nificant improvement in these frequent and uncurable disease. Overall survival of metastatic breast cancer 
disease is still short about 37 months. Today there is no biomarker that meets evidence for clinical use. The 
special issue of endocrine treatment is resistance, primary or acquired. The CDK4/6 inhibitors are newer 
class of drugs used to treat HR positive Her2 negative subtypes of metastatic breast cancer. This targeted 
therapy inhibits specific proteins cyclin-dependent kinases 4 and 6 which can become overactive and 
cause fast cells grow and dividing. Inhibitors of these protein interrupt these processes in the way to slow 
cancer cells grow. Hormone receptor positive tumors are dependent of hormones as estrogen, progester-
one, or both. HER2 negative breast cancers doesn’t have human epidermal growth factor receptor 2 
(HER2). The CDK4/6 inhibitors also can be used to treat locally advanced breast cancer which is not meta-
static. Endocrine therapy is the preferred option for hormone receptor positive disease. If there is condi-
tion of visceral crisis defined as severe organ dysfunction or rapid progression of disease we have to treat 
patients with chemotherapy.Palbociclib was the first inhibitor of CDK4/6 received an approval by FDA in 
2015. in combination with letrozole as initial therapy for AI sensitive metastatic breast cancer based on 
results from PALOMA-1 and PALOMA-2 clinical studies. PALOMA-3 trial expanded indications with 
fulvestrant for both postmenopausal and preperimenopausal women with AI-resistant advanced or meta-
static breast cancer. Ribociclib approved in 2017. due to results of MONALEESA-2 study as first line endo-
crine based therapy for AI-sensitive advanced or metastatic breast cancer in addition with an aromatase 
inhibitor. Based on MONALEESA-7 trial, these drug combinations approved for the treatment of pre-
menopausal women. MONALEESA-3 trial shows that ribociclib in combination with fulvestrant is effec-
tive in post-menopausal women with both AI-sensitive and AI-resistant metastatic breast cancer. In 2017. 
MONARCH-2 approved efficacy of abemaciclib in combination with fulvestrant in women with AI-resis-
tant advanced or metastatic breast cancer. The MONARCH-3 study showed that abemaciclib with non-
steroidal aromatase inhibitor significantly improved PFS in patients with AI-sensitive advanced or meta-
static breast cancer. Abemaciclib also has indication as a monotherapy based on MONARCH-1 trial for 
patients with HR-positive HER2-negative metastatic breast cancer who previously received endocrine 
therapy or chemotherapy. These specific cell inhibitors cause side effects which are not so intense as caused 
by chemotherapy. Most common side effects are nausea, diarrhea, fatigue, neutropenia, anemia, thrombo-
cytopenia ect. Also, there are alopecia, liver and cardiac toxicities. If there are high grade toxicities the 
procedure of stopping the drug or lowering the dose maybe useful to continue treatment and made the 
best efficacy of the approach. In some cases, these drugs can cause QT interval prolongation. These can 
influence the chosen of drug when patient has hearth comorbidities. Next step is to use these drugs in 
adjuvant setting when patients can be cured in the early stage of these malignant disease.
Keywords: breast, cancer, hormonal, CDK4/6, inhibitors
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Breast cancer cells have pronounced neurotropism and breast cancer is, after lung cancer, the second 
most common cause of brain metastases (especially HER2 positive and triple negative subtypes). The risk 
of developing brain metastases in breast cancer is as high as 25% with a median time from diagnosis of 
advanced cancer to brain dissemination of 2-3 years. Overall survival, despite therapeutic modalities 
involving surgery, radiation, and systemic therapy, ranges from 2–25 months, depending on prognostic 
factors including age, histological subtype, number of central metastases, and volume of extracranial dis-
ease. Potential systemic therapeutic options are limited by the blood-brain (BBB)  and blood-tissue barrier 
(BTB). In HER2 positive disease, about 50% of patients develop brain metastases, and monoclonal antibod-
ies targeting the HER2 receptor (trastuzumab, pertuzumab, T-DM1) do not pass intact BBB, however, by 
controlling extracranial disease, they delay time to central dissemination. Two important therapeutic 
options in HER2 positive disease are HER2-targeted tyrosine kinase inhibitors (lapatinib, neratinib, tuca-
tinib) in combination with capecitabine and antibody-cytotoxic drug conjugates, trastuzumab emtansine 
(T-DM1) and trastuzumab-deruxtecan (T-DXd). Lapatinib monotherapy has a minimal therapeutic 
response with an ORR of 6%, while combination with capecitabine in pretreated HER2 positive disease 
has a response rate of 18-38%. Pan-TKI neratinib in combination with capecitabine (NALA trial) in the 
third-line treatment of patients with asymptomatic brain metastases showed a benefit in PFS of 2.2 months 
and a statistically insignificant benefit to OS (24 vrs. 22.2 months) compared to the combination of lapa-
tinib and capecitabine. Neratinib in combination with paclitaxel in the first-line treatment (NEfERT trial) 
of HER2-positive brain metastases was not superior in PFS but it slowed central disease progression and 
halved central events in comparison with the combination of trastuzumab and paclitaxel. Tucatinib, a 
selective HER2 TKI in combination with trastuzumab and capecitabine compared to trastuzumab and 
capecitabine in previously HER2 pretreated patients (HER2CIMB trial) met pre-determined endpoints, 
reducing the risk of disease progression by 46% and the risk of death by 34% with ORR 41% vrs 23% in the 
total population. In patients with active brain metastases, the reduction in risk of death was 51% and the 
reduction in central progression 64% in the tucatinib arm. Trastuzumab deruxtecan (T-DXd) conjugate 
(DESTINY-Breast01 trial) used in heavily pretreated patients (median of 6 previous lines of therapy) 
showed impressive results with ORR of 61.4%, response rate of 58.3% in the brain metastases group, and 
the median survival without central progression of 18.1 months. New therapeutic options in the treatment 
of HER2 positive diseases including neratinib, tucatinib and trastuzumab deruxtecan show very promis-
ing results in patients with central disease. As for the central propagation of TNBC, it is thought that TNBC 
cells cause neuroinflammation, increase activity of proteolytic enzymes and directly destroy the blood-
brain barrier which causes loss of integrity of the blood-brain barrier, enables entry of tumor cells into the 
brain parenchim and stimulates neovascularization. VEGF expression is significantly higher in triple neg-
ative metastatic breast cancer than in HER2 positive. Also, TNBC metastases are thought to have less rep-
resentation to immune cells such as CD8+ T lymphocytes, regulatory and dendritic cells, which can con-
tribute to the immune escape of tumor cells. New therapeutic strategies over the past few years include 
among others PARP (poly ADP-ribose polymerase) inhibitors (talazoparib, veliparib, olaparib), VEGF 
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inhibitors (bevacizumab) and checkpoint inhibitors (anti PD-L1, atezolizumab). Addition of PARP inhibi-
tor velaparib to cisplatin in SWOG1416 trial did not significantly improve PFS or OS. The BRCA mutated 
subset of patients had an improvement in PFS from 4.2 months to 5.9 months and in OS from 12 to 14 
months. Final results (2020) of EMBRACA trial which used talazoparib in comparison to chemotherapy 
(capecitabine, cisplatin, gemcitabine), despite longer PFS with HR 0.54, showed no benefit in OS in the 
overall population as well as in patients with central disease. TNBC is the most immunogenic type of 
breast cancer and inhibition of cell death receptors (PD-1) and its ligand (PD-L1) is an attractive therapeu-
tic target. The results of IMpassion 130 trial which combined anti PD-L1 drug atezolizumab and nab-
paclitaxel, are a significant milestone in the treatment of advanced TNBC with the extension of PFS and OS 
by 9.5 months, including patients with central disease. Potential therapeutic options, including nanotech-
nology, which could reduce the incidence of brain metastases and prolong survival are continuously 
investigated.
Keywords:  brain metastases, HER2 positive disease, triple negative breast cancer, therapeutic stra-
tegies
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Despite the many challenges faced in 2020, we have seen impressive progress in many areas of cancer 
research. Twenty-one novel oncology drugs were approved by the U.S. Food and Drug Administration 
(FDA). Although cancer is one of the major public health problems worldwide, cancer mortality projec-
tions for 2021 confirm the persistent declines in cancer mortality in EU and US for many specific cancers. 
The breast cancer treatment landscape has evolved in the past year and several new drugs approved in 
2020 as antibody drugs conjugates (ADC) sacituzumab in TNBC and fam-trastuzumab deruxtecan-nxki 
(T-DXd) in metastatic HER2 positive BC, as well as tucatinib, a small kinase inhibitor. A few very impor-
tant clinical trial /RxPONDER, ADAPT, PRIME II/ presented last year support de-escalation of adjuvant 
chemotherapy and radiation, sparing patients from some of the side effects that can accompany treat-
ments. In ovarian cancer five-year follow-up data from the SOLO-1 trial continue to show progression-free survival 
benefit of olaparib as maintenance therapy following platinum-based chemotherapy in the frontline setting. In the 
final analysis of SOLO-2 trial, maintenance olaparib provided an improvement of 12.9 months in median 
OS vs placebo in women with relapsed BRCA-related ovarian cancer who had responded to their most 
recent platinum-based chemotherapy after having received at least one more line of chemotherapy.In 2020 
first new treatment for hepatocellular carcinoma approved in more than ten years according to the data 
from phase III IMbrave 150 trial. In that study, which includes 501 patients the combination of atezoli-
zumab and bevacizumab provides the longest survival seen in a front-line phase III study in advanced 
HCC, confirming atezo + bev as a standard of care for previously untreated, unresectable HCC.In the field 
of thoracic oncology there were some very important news in 2020, potentially practice changing. Osimer-
tinib, next generation EGFR-TKI, standard first line therapy in metastatic EGFR-mutated advanced NSCLC 
was successfully used, in ADAURA study, in adjuvant setting vs placebo (planned treatment duration 
three years), in resected NSCLC patients, stage IB-IIIA. Patients might had adjuvant chemotherapy also, 
and there was no outcome differences between these two groups. Overall, there was a 79% reduction in the 
risk of disease recurrence or death (DFS HR was 0.21, p<0.0001). Lorlatinib is the third generation of ALK-
inhibitors in the treatment of advanced NSCLC. The results of CROWN study where lorlatinib was given 
in the first line treatment were presented at ESMO 2020. In this randomized study, comparing lorlatinib 
with crizotinib, lorlatinib was superior in the term of PFS, HR was 0.28, p<0.001, this superiority was par-
ticularly pronounced in intracranial disease, where the percent of intracranial response was 82% in lorla-
tinib arm and only 23% in crizotinib arm, and percent of complete response per CT was 71% vs 7%. Lorla-
tinib has been recently approved for patients with advanced ALK-positive NSCLC, irrespectively of treat-
ment line. Also of interest were two studies that inovatively used immunologic drugs as a combination in 
advanced NSCLC: in Check Mate 9LA randomized study, cytotoxic chemotherapy was given in paralell 
with nivolumab + ipilimumab for first two cycles, and compared with four cycles of chemoherapy. Median 
OS was significantly better: 15.6 vs 10.9 months, HR 0.66 and a overall response rate was 38% vs 25%. 
CITYSCAPE study give us inovative combination of two immuno-oncology drugs, tiragolumab as TIGIT 
inhibitor, and standard atezolizumab. Median PFS was particularly longer in the population of patients 
with high PD-L1 expression (NE vs 4.11 months, HR 0.30). In gastrointestinal oncology, last year will be 
remembered by introducing immunotherapy in first line treatment of metastatic colorectal cancer for 
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patients with MSI-H tumors. In KN177, such patients were randomized to receive pembrolizumab or stan-
dard chemotherapy+/-biologic therapy, and after second interim analysis, there was a very clear advent-
age for pembrolizumab in terms of mPFS (16.5 vs 8.2 months) and duraton of response (at 24 months, 83% 
vs 35%). The results are impressive, and it is for expected to be confirmed by OS adventage in future 
analyses. In urological oncology, JAVELIN Bladder 100 study demonstrated that the maintenance ave-
lumab + best supportive care is superior over best supportive care alone after platinum-based first-line 
chemotherapy in advanced urothelial carcinoma. In overall population, OS was 21.4 vs 14.3 months, HR 
0.69, p<0.001, and the results are even better in PD-L1 positive population, with HR 0.56. These results are 
very probably practice changing, since cytotoxic chemotherapy have very modest achievements in the 
field of urothelial cancer.
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